Anti-CD3ε Antibodies for Targeted T-cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for antibodies and therapeutics that specifically target the CD3/TCR pathway for therapeutic and diagnostic indications, as direct engagement of CD3 results in T-cell activation, but existing solutions are inadequate.
Innovation Solution
Development of anti-CD3ε antibodies and antigen-binding fragments that specifically bind to the epsilon chain of CD3, activating T cells through engagement, including monoclonal, humanized, and chimeric antibodies with specific CDR sequences, and activatable antibodies coupled with masking moieties that reduce binding in normal tissues but activate at intended sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct engagement of CD3 is used to activate T cells, then T-cell activation is achieved, but off-target effects and lack of specificity occur
Solution Approach 1:
The patent applies local quality by designing antibodies that specifically target the epsilon chain (CD3ε) of the CD3 complex rather than all CD3 chains. This localized targeting approach maintains T-cell activation efficacy while reducing off-target effects by selectively engaging only the desired antigenic determinant on T cells.
Solution Approach 2:
The patent uses bispecific antibodies as intermediaries that simultaneously bind to CD3ε on T cells and to a second target antigen. This intermediary approach enables controlled, targeted activation of T cells only in the presence of the second target, thereby reducing non-specific off-target effects while maintaining reliable T-cell activation when the target is present.
2Reliability
If broad-spectrum anti-CD3 antibodies are used, then T-cell activation is achieved, but specificity is reduced
Solution Approach 1:
The patent employs local quality by engineering antibodies with precise specificity for the CD3ε chain alone, rather than binding to multiple CD3 chains. This is achieved through careful selection of antigen-binding domains that recognize unique epitopes on CD3ε, thereby maintaining reliable T-cell activation while significantly improving binding specificity.
Solution Approach 2:
The patent applies parameter changes by modifying the structural and functional parameters of the antibody molecules, including isotype selection (e.g., IgG1, IgG2), affinity characteristics, and epitope recognition profiles. These parameter optimizations enable the antibodies to maintain effective T-cell activation while achieving higher specificity for CD3ε over other CD3 chains.
3Object-affected harmful factors
If activatable antibodies with masking moieties are used, then off-target effects are reduced, but device complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody structure into distinct functional modules: a target-binding domain, a masking domain, and a linker region. This modular segmentation allows the masking moiety to be independently optimized and attached, reducing off-target effects while managing structural complexity through systematic domain organization rather than monolithic design.
Solution Approach 2:
The patent uses preliminary action by incorporating masking moieties that pre-block the antigen-binding sites before the antibody reaches the target tissue. This preliminary masking prevents off-target effects during circulation, and the mask is subsequently removed or inactivated at the target site, allowing specific activation only where needed. This approach reduces off-target effects while keeping the structural complexity manageable through controlled temporal activation.
Data Source
AI summary
The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.